Methotrexate in Children with Juvenile Idiopathic Arthritis
Authors:
J. Tuková; D. Němcová; J. Hoza; P. Doležalová
Authors‘ workplace:
Klinika dětského a dorostového lékařství UK 1. LF a VFN, Praha
přednosta prof. MUDr. J. Zeman, DrSc.
Published in:
Čes-slov Pediat 2010; 65 (6): 394-400.
Category:
Review
Overview
Despite the significant development of biologics, methotrexate (MTX) remains the most commonly used disease-modifying antirheumatic drug in children with juvenile idiopathic arthritis (JIA). There is considerable variability among clinicians in the use of methotrexate. Unique guidelines based on clinical trials would contribute to optimization of MTX use. Revision of scientific literature has shown lack of randomised controlled trials concerning this topic.
Our proposed therapeutic algorithm is based on analysis of accessible data on both paediatric and adult rheumatology patients and unclear points are solved with regard to experts´ opinion. Its final version will be revised by an international expert group and will be a subject to regular updates.
Key words:
methotrexate, juvenile idiopathic arthritis, guidelines
Sources
1. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis – why does it vary so much? J. Rheumatol. 2002; 29: 1520–1530.
2. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann. Rheum. Dis. 2004; 63: 1172–1176.
3. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A. – U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N. Engl. J. Med. 1992; 326(16): 1043–1049.
4. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo- controlled, crossover trial of low- dose oral methotrexate in children with extended oligoatricular or systemic arthritis. Arthr. and Rheum. 2000; 43(8): 1849–1857.
5. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50(7): 2191–2201.
6. Harel L, Weiner LW, Poznanski AK, Spencer CH, Ekwo E, Magilavy DB. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum. 1993; 36(10): 1370–1374.
7. Wallace CA, Sherry DD, Mellins ED, Aiken RP. Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J. Rheumatol. 1993; 20(1): 118–122.
8. Ravelli A, Viola S, Ramenghi B, Beluffi G, Zonta LA, Martini A. Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J. Pediatr. 1998; 133(2): 262–265.
9. Alsufyani K, Vares OO-A, Cabral DA, Tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J. Rheumatol. 2004; 31: 179–182.
10. Gottlieb BS, Keenam GF, Lu T, Ilowite NT. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 1997; 100(6): 994–997.
11. Ravelli A, Viola S, Migliavacca D, Ruperto N, Pistorio A, Martini A. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J. Pediatr. 1999; 135(3): 316–320.
12. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294(13): 1671–1684.
13. Davies K, Woo P. Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology 2002; 41: 937–941.
14. Halle F, Prieur A. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin. Exp. Rheumatol. 1991; 9: 297–302.
15. Cassidy JT, Petty RE. Juvenile rheumatoid arthritis. In: Cassidy JT, Petty RE (eds.) Textbook of Pediatric Rheumatology. Philadelphia: WB Saunders. 2001: 218–321.
16. Cron RQ, Sharma S, Sherry DD. Current treatment by United States and Canadian pediatric rheumatologists. J. Rheumatol. 1999; 26: 2036–2038.
17. Niehues T, Horneff G, Michels H, Hock MS, Schuchmann L. Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol. Int. 2005; 25: 169–178.
18. Niehues T, Lankisch P. Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Pediatric Drugs 2006; 8(6): 347–356.
19. Brik R, Gepstein V, Berkovitz D. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids. Clin. Rheumatol. 2005; 24: 612–614.
20. BSPAR guidelines on methotrexate use in paediatric rheumatology. 2005 [updated 2007; last viewed 2010 February 12]. Available from: http:// www.bspar.org.uk/downloads/clinical_guidelines/BSPAR_METHR.pdf.
21. Ramanam AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch. Dis. Child. 2002; 88: 197–200.
22. Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: Answers and questions. J. Rheumatol. 2000; 27(8): 1830–1833.
23. Ravelli A, Ramenghi B, Di Fuccia G, Ruperto N, Zonta L, Martini A. Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. Acta Paediatr. 1994; 83(4): 428–432.
24. Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: A cohort study of 683 consecutive cases with a mean 10 year follow up. J. Rheumatol. 2003; 30: 579–584.
25. Albers HM, Wessels JA, van der Straaten RJ, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum. 2009; 61(1): 46–51.
26. Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004; 43: 906–914.
27. Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1998; 32(6): 677–681.
28. Singsen BH, Goldbach-Mansky R. Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatic and nonrheumatic disorders. Rheum. Dis. Clin. North Am. 1997; 23: 811–841.
29. Doležalová P. Methotrexát u juvenilní idiopatické artritidy. Lék. Listy 2007; 8: 15–17.
30. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum. 1998; 3: 381–391.
31. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J. Rheumatol. 1989; 16: 313–320.
32. Tuková J, Chládek J, Nemcová D, Chládková J, Doležalová P. Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile arthritis. Clin. Exp. Rheumatol. 2009; 27: 1047–1053.
33. Dupuis LL, Koren G, Silverman ED, Laxer RM. Influence of food on the bioavalability of oral methotrexate in children. J. Rheumatol. 1995; 22: 1570–1573.
34. Foell D, Frosch M, Wiesch ASz, Vogl T, Sorg C, Roth J. Methotrexate in juvenile idiopathic arthritis: when is the right time to stop? Ann. Rheum. Dis. 2004; 63: 206–208.
35. Wallace CA, Bin H, Marcia B, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52(11): 3554–3562.
36. Magnani A, Pistorio A, Magni-Manzoni S, et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J. Rheumatol. 2009; 36(3): 628–634.
37. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the Management of Rheumatoid Arthritis. Arthritis Rheum. 2002; 46:328–346.
38. Hashkes PJ, Balistreri WF, Bove KE, Ballard ET, Passo MH. The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J. Pediatr. 1999; 134: 47–52.
39. Hashkes PJ, Balistreri WF, Bove KE, Ballard ET, Passo MH. The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1997; 40: 2226–2234.
40. Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J. Pediatr. 1992; 120: 468–473.
41. Heijstek MW, Pileggi C, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann. Rheum. Dis. 2007; 66: 1384–1387.
42. Zonneveld-Huijssoon E, Ronaghy A, Rossum MAJ, et al. Safety and efficacy of meningococcal C vaccination in juvenile idiopathic arthritis. Arthritis Rheum. 2007; 56: 639–646.
43. Koca B, Kasapcopur O, Aslan M, et al. Pneumococcal vaccine response and antibody levels in juvenile idiopathic arthritis. Ann. Rheum. Dis. 2006; 65(Suppl 2): 112.
44. Kasapçopur Ö, Çullu F, Kamburoðlu-Goksel A, et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann. Rheum. Dis. 2004; 63: 1128–1130.
45. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin. Exp. Rheumatol. 2001; 19: 589–594.
46. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 2008; 359(8): 810–820.
47. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56: 3096–3106.
48. Hillson JL, Furst DE. Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Rheum. Dis. Clin. North Am. 1997; 23: 757–778.
49. Cronstein BN. The mechanism of action of methotrexate. Rheum. Dis. Clin. North Am. 1997; 23: 739–756.
50. Morgan SL, Bagott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: A double-blind, placebo-controlled trial. Ann. Intern. Med. 1994; 121: 833–841.
51. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J. Rheumatol. 1998; 25: 36–43.
52. Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the efficacy of methorexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J. Rheumatol. 1997; 24: 2230–2232.
53. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann. Rheum. Dis. 1991; 50: 913–914.
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2010 Issue 6
Most read in this issue
- Body Temperature and Thermoregulation in the Newborn
- Rapidly Progressive Complications of the Influenza A Type in Children
- Methotrexate in Children with Juvenile Idiopathic Arthritis
- Thromboembolic Events in Girls and Young Women Taking Hormonal Contraception